Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIAF 
bioAffinity Technologies, Inc. (BIAF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: BIAF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.06% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.74M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 2.33 | 52 Weeks Range 1.25 - 46.53 | Updated Date 12/5/2025 |
52 Weeks Range 1.25 - 46.53 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.0942 | Actual -4.74 |
Profitability
Profit Margin -217.5% | Operating Margin (TTM) -158.56% |
Management Effectiveness
Return on Assets (TTM) -71.71% | Return on Equity (TTM) -245.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 74727 | Price to Sales(TTM) 1.14 |
Enterprise Value 74727 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 4498709 | Shares Floating 4021152 |
Shares Outstanding 4498709 | Shares Floating 4021152 | ||
Percent Insiders 3.75 | Percent Institutions 9.36 |
Upturn AI SWOT
bioAffinity Technologies, Inc.
Company Overview
History and Background
bioAffinity Technologies, Inc. was founded in 2014 and focuses on early cancer detection and cancer diagnostics. Their platform technology is based on CyPathu00ae, a novel approach to detecting cancer biomarkers.
Core Business Areas
- Cancer Diagnostics: Developing and commercializing diagnostic tests for early cancer detection, primarily focusing on lung cancer.
Leadership and Structure
Maria Zannes is the President and CEO. The company has a small team and relies on partnerships for manufacturing and commercialization.
Top Products and Market Share
Key Offerings
- CyPathu00ae Lung: A diagnostic test for early-stage lung cancer detection using patient-collected sputum. Market share data is not publicly available as the test is still relatively new to market. Competitors include companies providing liquid biopsy tests and imaging diagnostics for lung cancer, such as Guardant Health (GH) and Exact Sciences (EXAS) in the liquid biopsy space, and companies that sell imaging such as GE HealthCare Technologies Inc. (GEHC).
Market Dynamics
Industry Overview
The cancer diagnostics market is rapidly growing, driven by increasing cancer incidence, rising awareness, and technological advancements in early detection methods.
Positioning
bioAffinity is positioned in the early lung cancer detection market with a non-invasive sputum-based test. The competitive advantage lies in the ease of sample collection and potential for earlier detection compared to traditional methods.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is estimated to be in the billions of dollars. bioAffinity is aiming to capture a significant portion of this market with CyPathu00ae Lung.
Upturn SWOT Analysis
Strengths
- Non-invasive sample collection (sputum)
- Potential for earlier cancer detection
- Proprietary CyPathu00ae technology
Weaknesses
- Limited commercialization experience
- Small company size and resources
- Dependence on partnerships
- Currently only focused on lung cancer
Opportunities
- Expansion to other cancer types
- Partnerships with larger diagnostic companies
- Increasing demand for early cancer detection
- FDA approval and reimbursement
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements rendering their solution less effective
Competitors and Market Share
Key Competitors
- GH
- EXAS
- GEHC
Competitive Landscape
bioAffinity has the advantage of non-invasive sample collection, but is relatively small. Competitors are often larger, well-established companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on research and development.
Future Projections: Future growth is dependent on successful commercialization of CyPathu00ae Lung and expansion to other cancer types. Analyst estimates are not readily available.
Recent Initiatives: Focus on clinical trials and regulatory approvals for CyPathu00ae Lung.
Summary
bioAffinity Technologies is a small, development-stage company with a novel technology for early lung cancer detection. Its strengths lie in the non-invasive nature of its test and the potential for earlier detection. However, it faces challenges related to commercialization, competition from larger companies, and regulatory hurdles. Successfully navigating these challenges will be crucial for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Data
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information. Future results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies, Inc.
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 57 | Website https://www.bioaffinitytech.com |
Full time employees 57 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.